Kurma Partners

Kiro is an IT company that offers artificial intelligence, ergonomic design, and software development solutions for medical biology.

Ganymed Robotics SAS, a medical device company, focuses on the development of robotics technologies for orthopedic surgeons. It develops a therapeutic device to enhance surgical precision in knee replacement surgery. The company was incorporated in 2018 and is based in Paris, France.

Ermium Therapeutics is a biotech company developing innovative therapies for auto-immune diseases, based on a breakthrough discovery showing that CXCR4 is a master regulator of inflammation. Ermium Therapeutics was founded in June 2019 by Jean-Philippe HERBEUVAL, Kurma Partners, Idinvest Partners, Domain Therapeutics and Erganeo. The company is based in Paris and has signed a worldwide exclusive license agreement on intellectual property from CNRS and University Paris Descartes (France) through an agreement with Erganeo, which supported the maturation of the project in an academic setting. In addition, Ermium Therapeutics recently won the innovation i-Lab 2019 award from the French Ministry of Research and Higher Education.

Charles helps men regain control over their daily health concerns by starting with their personal health. The company was founded in Paris, Ile-de-France, France in 2019.

ImCheck Therapeutics SAS is a biotechnology company incorporated in 2015 and based in Marseille, France. The company specializes in designing and developing immunotherapeutics that target the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. With a primary focus on immuno-oncology, ImCheck Therapeutics develops immunomodulatory antibodies aimed at treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company is dedicated to addressing severe unmet medical needs through its innovative approach to cancer treatment and the development of next-generation immunotherapeutics.

Germitec is a manufacturer focused on developing advanced disinfection systems aimed at enhancing hospital hygiene. The company specializes in ultraviolet light high-level disinfection (UV-C HLD) technology, which is designed for the reprocessing of non-lumen medical devices. By utilizing this innovative approach, Germitec seeks to simplify the responsibilities of healthcare professionals, improving safety and efficiency while significantly reducing the risk of cross-infection in clinical settings.

DAMAE Medical SAS, founded in 2014 and based in Paris, France, specializes in developing advanced medical imaging technologies for dermatology. The company's flagship product, OCTAV, employs innovative optical imaging techniques to provide in vivo, cellular-level images of skin tissues, offering insights similar to traditional histology without requiring tissue excision or processing. This non-invasive approach enables dermatologists to assess the malignancy of skin tumors with precision and efficiency through simple contact with the skin's surface. By leveraging bio-photonics, DAMAE Medical aims to enhance diagnostic capabilities in dermatology, facilitating timely and accurate evaluations of skin cancer.

NaoX Technologies develops wireless headphones that listen to brain vibrations.

Armgo Pharma, Inc. is a biopharmaceutical company focused on developing small-molecule therapeutics for debilitating cardiac, skeletal muscular, and neurological disorders. The company specializes in calcium release channel stabilizers known as Rycals, which target the ryanodine receptor/calcium release channel located on the sarcoplasmic/endoplasmic reticulum of cells. These therapeutics are designed to address various conditions, including chronic heart failure, cardiac arrhythmias, muscle disorders, cognitive disorders, malignant hyperthermia, diabetes, chronic obstructive pulmonary disease, high blood pressure, and bladder dysfunction. Founded in 2004, Armgo Pharma is headquartered in Tarrytown, New York, with an additional office in New York City.

Sunrise aims to bring simple answers to millions of people suffering from sleep disorders. We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate as in-lab sleep studies, at a fraction of the cost. Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases. Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems.

Corteria Pharmaceuticals is a biotechnology company dedicated to developing innovative therapies for heart failure subpopulations, particularly those experiencing worsening and acute decompensated heart failure. The company focuses on addressing unmet medical needs in this area and aims to provide effective treatments that enhance understanding of the underlying disease biology. Additionally, Corteria's research extends to related conditions such as sarcopenia and obesity, positioning the company to make a significant impact on the management of these interconnected health issues.

Emergence Therapeutics AG develops novel antibody drug conjugate (ADC) immuno-therapeutics to treat high need cancers. The company was incorporated in 2019 and is based in Duisburg, Germany.

Stilla Technologies is a Paris-based European Biotechnology company that focuses on accelerating the development of next-generation genetic tests by providing a ground-breaking and flexible digital PCR (dPCR) solution: the Naica System. Taking advantage of cutting-edge microfluidic innovations, Stilla aims to make dPCR a lab commodity to all Life Sciences areas: research, therapeutics, and all the “omics”.

PathoQuest SAS, a biotechnology company, offers a game changing metagenomics approach to improving the breadth of pathogen detection. The company offers products, such as (NGS) based testing approach delivers actionable reports to clinicians, biologists, and biopharmaceutical quality assurance managers and production managers. It provides iDTECTTM Dx Blood test, an approach to the identification of pathogens and iDTECTTM database and software suite that enables clinicians and biopharma companies to overcome the current limitation of infectious agent detection. The company also offers Viral Safety testing service for biopharmaceutical companies. It has strategic alliance with Charles River Laboratories International, Inc. PathoQuest SAS was founded in 2010 and is based in Paris, France.

DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Our revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's leading programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, which features a novel mechanism of action that may help restore fat and glucose metabolism. Through its innovative approach, Amolyt Pharma seeks to provide effective treatments for patients suffering from critical and rare metabolic conditions.

Horama SAS is a biotechnology company based in Paris, France, established in 2014. It specializes in developing gene therapy products aimed at treating rare ophthalmic diseases, particularly targeting inherited retinal dystrophies and retinopathies. By utilizing recombinant adeno-associated viral vectors, Horama's therapies aim to deliver a functional copy of mutated genes to affected retinal cells. This approach seeks to restore normal cell function, prevent further deterioration of vision, and ultimately improve or restore visual capabilities for patients. The company is positioning itself as a significant player in the ophthalmic gene therapy sector, with the goal of enhancing patient autonomy while also contributing to reduced healthcare costs.

SmartCatch brings value-added liquid biopsy technology to empower clinicians, researchers, and industry in the fight against cancer.

Arkhn is a platform specialist in healthcare data interoperability. Arkhn tackles the issue of accessing healthcare data.

Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player in the funding of healthcare and biotechnology in Europe.

Poppins is a developer of digital therapeutic technology aimed at enhancing cognitive function in children with learning disorders. The company creates interactive musical games that integrate neurologic music therapy methods to address conditions such as dyslexia, dysphasia, and dyspraxia. These games focus on improving essential skills like concentration, motor skills, and memory through engaging activities that can be performed at home. By leveraging data science and advanced technologies, Poppins interprets learning, language, and motor performance to generate a cognitive score, facilitating personalized treatment plans. The company's mission is to provide accessible digital solutions for children facing learning challenges, ultimately aiming to improve their reading abilities and memory retention while supporting speech therapy.

Medlumics S.L. designs and manufactures catheter based systems for the treatment of supra ventricular tachycardias. The company develops integrated photonic devices using optical coherence tomography technology, a light based diagnostic technique to provide sectional information about tissue. Medlumics S.L. was founded in 2009 and is based in Tres Cantos, Spain.

IO Biotech ApS is a clinical stage biotech company developing disruptive immune therapies i.e. checkpoint/cancer vaccines. Checkpoint/cancer vaccines suppress the function of regulatory immune cells and induce inflammation in the microenvironment in addition to direct targeting of cancer cells.

Lucine is focused on transforming patient health, primarily in the area of pain management. The company has developed a mobile health application that measures, analyzes, and alleviates pain from the comfort of home. Utilizing advanced algorithms, the application identifies the nature of a patient's pain by analyzing facial expressions, vocal cues, and posture. Based on this real-time assessment, it personalizes treatment options, offering techniques such as exercises, relaxation methods, art therapy, and meditation. The application aims to provide relief within five minutes through innovative analgesic neurostimulation, empowering patients with chronic pain to manage their symptoms effectively.

Synendos Therapeutics AG is a biopharmaceutical company based in Allschwil, Switzerland, founded in 2019. The company focuses on developing innovative therapies for unmet needs in neuropsychiatric disorders, particularly anxiety, mood, and stress-related conditions. Synendos utilizes a novel drug target within the endocannabinoid system to restore the brain's natural functioning. Its therapies involve the modulation of cannabinoid activity and the inhibition of endocannabinoid transport across cell membranes, addressing altered neurotransmission in various brain regions. This approach presents a promising solution to the significant demand for effective pharmacological treatments, especially for conditions like post-traumatic stress disorder (PTSD), which currently lacks adequate therapeutic options.

Corlieve Therapeutics SAS, a biotechnology company, develops therapeutic options to patients with severe neurological disorders. Its lead project is targeting aberrantly expressed kainate receptors in the hippocampus of patients with temporal lobe epilepsy (TLE) using a gene therapy approach. The company’s program employs a novel AAV gene therapy approach for the treatment of refractory TLE and is based on science from INSERM, CNRS, Aix Marseille University, and the University of Bordeaux. The company was incorporated in 2019 and is based in Paris, France.

Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies for rare neurological disorders. The company discovers, develops, and delivers therapies for CNS disorders. Its initial focus is on SCA which is a subgroup of hereditary ataxia, HD which is a neurodegenerative disorder, and RTT-a neurodevelopmental disorder primarily affecting girls that enable clients with providing therapy for it. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Judith van Deutekom, and Gail Mandel and it is headquartered in Leiden, The Netherlands.

DeepUll is a biotech company that focuses its activity on the development of a new diagnostic system for early-stage sepsis condition. DeepUll’s proposal is based on quickly identifying the pathogens and offering the antibiogram within a few hours on the one hand, and on using the data and learning about the patient’s immunological and functional status on the other. The system allows doctors to predict the future appearance and evolution of sepsis within a short period of time and thus provide a suitable clinical response even before the symptoms arise.

Dynacure is a clinical-stage drug development company focused on improving the lives of patients with rare and orphan diseases.The Dynacure team leverages its proven track record in rare disease drug development to build a pipeline of novel drugs. Dynacure is developing DYN101, an investigational antisense medicine designed to modulate the expression of dynamin 2 for the treatment of Centronuclear Myopathies, with Ionis Pharmaceuticals. Dynacure is also building a complementary research portfolio targeting other orphan disorders.

AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.

Stilla Technologies is a Paris-based European Biotechnology company that focuses on accelerating the development of next-generation genetic tests by providing a ground-breaking and flexible digital PCR (dPCR) solution: the Naica System. Taking advantage of cutting-edge microfluidic innovations, Stilla aims to make dPCR a lab commodity to all Life Sciences areas: research, therapeutics, and all the “omics”.

Sensome SAS is a French company that specializes in the development and manufacturing of innovative medical micro-sensors aimed at enhancing invasive vascular medical devices. Founded in 2014 and headquartered in Massy, France, Sensome's technology utilizes AI-driven micro-sensors to provide real-time, non-invasive identification of tissue composition during medical procedures, particularly in stroke treatment. This breakthrough remote monitoring technology addresses the limitations of traditional vascular imaging techniques, facilitating better interventions and patient follow-ups. The company's proprietary sensor technology, which combines impedance-based micro-sensors with machine learning algorithms, offers high predictive reliability for identifying biological tissues. Sensome is focused on developing vascular access devices equipped with this technology, with plans to extend its applications to various medical fields, including neurovascular, peripheral vascular, and cardiovascular interventions.

Cardiologs Technologies SAS is a medical technology company based in Paris, France, that specializes in electrocardiogram (ECG) analysis to enhance cardiac patient management. Founded in 2014, the company offers the Cardiologs ECG Analysis Platform, a cloud-based service designed to assist physicians in screening for atrial fibrillation and other arrhythmias through long-term ambulatory ECG monitoring. Utilizing a proprietary database of over 1.4 million recordings and advanced deep learning technology, Cardiologs' solution is backed by clinical publications demonstrating its diagnostic effectiveness. The platform enables cardiologists to identify patterns in digital ECG signals from various compatible cardiac monitoring devices, ultimately aiming to make expert cardiac diagnostics more scalable and accessible within the healthcare sector.

ImCheck Therapeutics SAS is a biotechnology company incorporated in 2015 and based in Marseille, France. The company specializes in designing and developing immunotherapeutics that target the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. With a primary focus on immuno-oncology, ImCheck Therapeutics develops immunomodulatory antibodies aimed at treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company is dedicated to addressing severe unmet medical needs through its innovative approach to cancer treatment and the development of next-generation immunotherapeutics.

Tacalyx GmbH operates as an oncology company, which focuses on the discovery and development of Tumor Associated Carbohydrate Antigen (TACA) antibodies to treat cancer. It provides technology platform for TACAs as novel targets for cancer therapy. The company is based in Berlin, Germany.

FeetMe SAS, based in Paris, France, specializes in developing advanced insoles designed to monitor foot pressure in real time, particularly for diabetic patients. Founded in 2013, the company utilizes embedded pressure sensors in its insoles to create detailed pressure maps, enabling both patients and healthcare providers to detect changes in plantar pressure. This innovative technology addresses the significant global issue of mobility disorders, affecting approximately 100 million individuals. FeetMe's primary product, the FeetMe Monitor, combines connected insoles with mobile software to assess gait parameters and variability in real-life situations through smart algorithms and wireless connectivity. The company's solutions are marketed to pharmaceutical firms for clinical trials, rehabilitation centers for mobility assessments, and directly to patients for home rehabilitation, aiming to enhance therapeutic and rehabilitation evaluations.

Ermium Therapeutics is a biotech company developing innovative therapies for auto-immune diseases, based on a breakthrough discovery showing that CXCR4 is a master regulator of inflammation. Ermium Therapeutics was founded in June 2019 by Jean-Philippe HERBEUVAL, Kurma Partners, Idinvest Partners, Domain Therapeutics and Erganeo. The company is based in Paris and has signed a worldwide exclusive license agreement on intellectual property from CNRS and University Paris Descartes (France) through an agreement with Erganeo, which supported the maturation of the project in an academic setting. In addition, Ermium Therapeutics recently won the innovation i-Lab 2019 award from the French Ministry of Research and Higher Education.

Pharvaris B.V. is a clinical-stage company based in Leiden, the Netherlands, focused on the discovery and development of oral bradykinin B2 receptor antagonists for the treatment of hereditary angioedema (HAE) and other conditions linked to B2 receptor activity. Established in 2015, the company aims to provide new therapeutic options that eliminate the need for injections. Its lead drug candidate, PHA121, is a novel small-molecule antagonist currently undergoing Phase 1 clinical trials. Pharvaris benefits from the expertise of its co-founders, including an inventor of icatibant, which is a previously developed treatment for HAE. The company is dedicated to advancing alternatives to existing therapies, enhancing the quality of life for patients with HAE.

PathoQuest SAS, a biotechnology company, offers a game changing metagenomics approach to improving the breadth of pathogen detection. The company offers products, such as (NGS) based testing approach delivers actionable reports to clinicians, biologists, and biopharmaceutical quality assurance managers and production managers. It provides iDTECTTM Dx Blood test, an approach to the identification of pathogens and iDTECTTM database and software suite that enables clinicians and biopharma companies to overcome the current limitation of infectious agent detection. The company also offers Viral Safety testing service for biopharmaceutical companies. It has strategic alliance with Charles River Laboratories International, Inc. PathoQuest SAS was founded in 2010 and is based in Paris, France.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's leading programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, which features a novel mechanism of action that may help restore fat and glucose metabolism. Through its innovative approach, Amolyt Pharma seeks to provide effective treatments for patients suffering from critical and rare metabolic conditions.

AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.

DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Our revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.

Stilla Technologies is a Paris-based European Biotechnology company that focuses on accelerating the development of next-generation genetic tests by providing a ground-breaking and flexible digital PCR (dPCR) solution: the Naica System. Taking advantage of cutting-edge microfluidic innovations, Stilla aims to make dPCR a lab commodity to all Life Sciences areas: research, therapeutics, and all the “omics”.

Minoryx Therapeutics is a biotechnology company based in Mataro, Spain, founded in 2011. The company specializes in discovering and developing innovative treatments for life-threatening rare diseases, with a particular focus on pediatric neurometabolic conditions of genetic origin. Minoryx is known for its development of pharmacological chaperones, a new generation of small molecule drugs designed to restore protein functionality, thereby addressing unmet medical needs in genetic diseases that severely affect the central nervous system. Additionally, Minoryx engages in repositioning-based projects to explore alternative therapeutic options for these challenging conditions.

Asarina Pharma AB (publ) researches and develops pharmaceutical products. Its flagship product is Sepranolone that is in Phase IIb clinical trial to treat premenstrual dysphoric disorder and menstrual migraine. The company was formerly known as Umecrine Mood AB and changed its name to Asarina Pharma AB (publ) in 2016. Asarina Pharma AB (publ) was incorporated in 2005 and is based in Solna, Sweden.

Dynacure is a clinical-stage drug development company focused on improving the lives of patients with rare and orphan diseases.The Dynacure team leverages its proven track record in rare disease drug development to build a pipeline of novel drugs. Dynacure is developing DYN101, an investigational antisense medicine designed to modulate the expression of dynamin 2 for the treatment of Centronuclear Myopathies, with Ionis Pharmaceuticals. Dynacure is also building a complementary research portfolio targeting other orphan disorders.

Safe Orthopaedics SA, a medical technology company, develops and markets sterile implants and single-use instruments for the treatment of spinal fracture pathologies in France and internationally. The company offers SteriSpine PS, an all-round kit for the treatment of spinal fractures and degenerative pathologies; and SteriSpine VA, a product platform for ready to use Kyphoplasty and Cement systems. It also provides SteriSpine LC, a ready to use instrumentation for lumbar cage portfolio, including Cedar and Elm; and SteriSpine CC, a ready to use instrumentation for cervical cage, such as Walnut. The company was founded in 2010 and is headquartered in Éragny-sur-Oise, France.

Sensome SAS is a French company that specializes in the development and manufacturing of innovative medical micro-sensors aimed at enhancing invasive vascular medical devices. Founded in 2014 and headquartered in Massy, France, Sensome's technology utilizes AI-driven micro-sensors to provide real-time, non-invasive identification of tissue composition during medical procedures, particularly in stroke treatment. This breakthrough remote monitoring technology addresses the limitations of traditional vascular imaging techniques, facilitating better interventions and patient follow-ups. The company's proprietary sensor technology, which combines impedance-based micro-sensors with machine learning algorithms, offers high predictive reliability for identifying biological tissues. Sensome is focused on developing vascular access devices equipped with this technology, with plans to extend its applications to various medical fields, including neurovascular, peripheral vascular, and cardiovascular interventions.

PathoQuest SAS, a biotechnology company, offers a game changing metagenomics approach to improving the breadth of pathogen detection. The company offers products, such as (NGS) based testing approach delivers actionable reports to clinicians, biologists, and biopharmaceutical quality assurance managers and production managers. It provides iDTECTTM Dx Blood test, an approach to the identification of pathogens and iDTECTTM database and software suite that enables clinicians and biopharma companies to overcome the current limitation of infectious agent detection. The company also offers Viral Safety testing service for biopharmaceutical companies. It has strategic alliance with Charles River Laboratories International, Inc. PathoQuest SAS was founded in 2010 and is based in Paris, France.

Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse). Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.

Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player in the funding of healthcare and biotechnology in Europe.

Xeltis AG operates as a clinical-stage medical device company that develops bio-absorbable heart valves and blood vessels. The company’s RestoreX, a polymer-based technology enables the patient's natural healing system to develop tissue that pervades Xeltis' heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis AG was founded in 2006 and is headquartered in Zurich, Switzerland with an additional R&D and manufacturing location in Eindhoven, the Netherlands.

Horama SAS is a biotechnology company based in Paris, France, established in 2014. It specializes in developing gene therapy products aimed at treating rare ophthalmic diseases, particularly targeting inherited retinal dystrophies and retinopathies. By utilizing recombinant adeno-associated viral vectors, Horama's therapies aim to deliver a functional copy of mutated genes to affected retinal cells. This approach seeks to restore normal cell function, prevent further deterioration of vision, and ultimately improve or restore visual capabilities for patients. The company is positioning itself as a significant player in the ophthalmic gene therapy sector, with the goal of enhancing patient autonomy while also contributing to reduced healthcare costs.

Cardiologs Technologies SAS is a medical technology company based in Paris, France, that specializes in electrocardiogram (ECG) analysis to enhance cardiac patient management. Founded in 2014, the company offers the Cardiologs ECG Analysis Platform, a cloud-based service designed to assist physicians in screening for atrial fibrillation and other arrhythmias through long-term ambulatory ECG monitoring. Utilizing a proprietary database of over 1.4 million recordings and advanced deep learning technology, Cardiologs' solution is backed by clinical publications demonstrating its diagnostic effectiveness. The platform enables cardiologists to identify patterns in digital ECG signals from various compatible cardiac monitoring devices, ultimately aiming to make expert cardiac diagnostics more scalable and accessible within the healthcare sector.

FeetMe SAS, based in Paris, France, specializes in developing advanced insoles designed to monitor foot pressure in real time, particularly for diabetic patients. Founded in 2013, the company utilizes embedded pressure sensors in its insoles to create detailed pressure maps, enabling both patients and healthcare providers to detect changes in plantar pressure. This innovative technology addresses the significant global issue of mobility disorders, affecting approximately 100 million individuals. FeetMe's primary product, the FeetMe Monitor, combines connected insoles with mobile software to assess gait parameters and variability in real-life situations through smart algorithms and wireless connectivity. The company's solutions are marketed to pharmaceutical firms for clinical trials, rehabilitation centers for mobility assessments, and directly to patients for home rehabilitation, aiming to enhance therapeutic and rehabilitation evaluations.

DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Our revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.

Sensome SAS is a French company that specializes in the development and manufacturing of innovative medical micro-sensors aimed at enhancing invasive vascular medical devices. Founded in 2014 and headquartered in Massy, France, Sensome's technology utilizes AI-driven micro-sensors to provide real-time, non-invasive identification of tissue composition during medical procedures, particularly in stroke treatment. This breakthrough remote monitoring technology addresses the limitations of traditional vascular imaging techniques, facilitating better interventions and patient follow-ups. The company's proprietary sensor technology, which combines impedance-based micro-sensors with machine learning algorithms, offers high predictive reliability for identifying biological tissues. Sensome is focused on developing vascular access devices equipped with this technology, with plans to extend its applications to various medical fields, including neurovascular, peripheral vascular, and cardiovascular interventions.

Safe Orthopaedics SA, a medical technology company, develops and markets sterile implants and single-use instruments for the treatment of spinal fracture pathologies in France and internationally. The company offers SteriSpine PS, an all-round kit for the treatment of spinal fractures and degenerative pathologies; and SteriSpine VA, a product platform for ready to use Kyphoplasty and Cement systems. It also provides SteriSpine LC, a ready to use instrumentation for lumbar cage portfolio, including Cedar and Elm; and SteriSpine CC, a ready to use instrumentation for cervical cage, such as Walnut. The company was founded in 2010 and is headquartered in Éragny-sur-Oise, France.

Vivet Therapeutics is dedicated to developing innovative gene therapy treatments for orphan diseases. Vivet Therapeutics is focused on optimizing gene therapy through a partnership with the Fundacion para la Investigacion Medica Aplicada (FIMA) at the Centro de Investigación Medica Aplicada (CIMA, Universidad de Navarra) to develop new AAV vectors specifically targeting the liver and generating new technologies to optimize gene delivery and long term expression.

ImCheck Therapeutics SAS is a biotechnology company incorporated in 2015 and based in Marseille, France. The company specializes in designing and developing immunotherapeutics that target the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. With a primary focus on immuno-oncology, ImCheck Therapeutics develops immunomodulatory antibodies aimed at treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company is dedicated to addressing severe unmet medical needs through its innovative approach to cancer treatment and the development of next-generation immunotherapeutics.

DAMAE Medical SAS, founded in 2014 and based in Paris, France, specializes in developing advanced medical imaging technologies for dermatology. The company's flagship product, OCTAV, employs innovative optical imaging techniques to provide in vivo, cellular-level images of skin tissues, offering insights similar to traditional histology without requiring tissue excision or processing. This non-invasive approach enables dermatologists to assess the malignancy of skin tumors with precision and efficiency through simple contact with the skin's surface. By leveraging bio-photonics, DAMAE Medical aims to enhance diagnostic capabilities in dermatology, facilitating timely and accurate evaluations of skin cancer.

Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse). Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.

OxThera AB manufactures products for the treatment of primary and secondary hyperoxaluria with bacteria and enzymes. It offers Oxabact, an orally delivered composition of live bacteria to promote the removal of endogenously produced oxalate for the treatment of primary hyperoxaluria and Oxazyme, a non-systemic orally delivered drug composed of recombinant oxalate decarboxylase for the treatment of dietary hyperoxaluria and prevention of kidney stones. The company was founded in 2005 and is based in Stockholm, Sweden with an additional location in Knoxville, Tennessee.

Advanced Perfusion Diagnostics is a medical technology company based in Lyon (France), that develops, manufactures and markets innovative patient monitoring systems. The core focus of APD is to provide relevant indicators pertaining to tissue perfusion to clinicians. The recent market introduction of IKORUS® monitoring system addresses a unmet need up to now, and opens new fields of investigation for physicians, enabling early detection of microcirculatory alterations and potential improvement of current therapeutic practices.

Dynacure is a clinical-stage drug development company focused on improving the lives of patients with rare and orphan diseases.The Dynacure team leverages its proven track record in rare disease drug development to build a pipeline of novel drugs. Dynacure is developing DYN101, an investigational antisense medicine designed to modulate the expression of dynamin 2 for the treatment of Centronuclear Myopathies, with Ionis Pharmaceuticals. Dynacure is also building a complementary research portfolio targeting other orphan disorders.

Asarina Pharma AB (publ) researches and develops pharmaceutical products. Its flagship product is Sepranolone that is in Phase IIb clinical trial to treat premenstrual dysphoric disorder and menstrual migraine. The company was formerly known as Umecrine Mood AB and changed its name to Asarina Pharma AB (publ) in 2016. Asarina Pharma AB (publ) was incorporated in 2005 and is based in Solna, Sweden.

DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Our revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.

STAT-Dx Life S.L. is a Barcelona-based company that specializes in the development, manufacturing, and marketing of molecular diagnostic systems. Established in 2010, the company focuses on creating near-patient testing products aimed at providing timely and efficient patient care, particularly in critical care environments. Its flagship product, the DiagCORE, is a portable multi-analyte instrument designed for molecular and immunoassay testing across various clinical settings. STAT-Dx offers several diagnostic panels, including the DiagCORE Cartridge for syndrome testing, the DiagCORE Analyzer for modular analysis, and specific panels for respiratory, gastrointestinal, central nervous system, pneumonia, and blood culture identification. In 2018, STAT-Dx became a subsidiary of QIAGEN N.V., further enhancing its capabilities in the diagnostics field.

Pharvaris B.V. is a clinical-stage company based in Leiden, the Netherlands, focused on the discovery and development of oral bradykinin B2 receptor antagonists for the treatment of hereditary angioedema (HAE) and other conditions linked to B2 receptor activity. Established in 2015, the company aims to provide new therapeutic options that eliminate the need for injections. Its lead drug candidate, PHA121, is a novel small-molecule antagonist currently undergoing Phase 1 clinical trials. Pharvaris benefits from the expertise of its co-founders, including an inventor of icatibant, which is a previously developed treatment for HAE. The company is dedicated to advancing alternatives to existing therapies, enhancing the quality of life for patients with HAE.

Xeltis AG operates as a clinical-stage medical device company that develops bio-absorbable heart valves and blood vessels. The company’s RestoreX, a polymer-based technology enables the patient's natural healing system to develop tissue that pervades Xeltis' heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis AG was founded in 2006 and is headquartered in Zurich, Switzerland with an additional R&D and manufacturing location in Eindhoven, the Netherlands.

BioSerenity souhaite aider la communauté scientifique à mieux comprendre l'épilepsie pour mieux la soigner. Une fois anonymisées et privées de tout lien avec le patient, les données recueillies seront mise à disposition des chercheurs de l'Institut du Cerveau et de la Moelle épinière (ICM). C'est un pas décisif pour faire avancer la recherche sur l'épilepsie et améliorer le futur du diagnostic

Advanced Perfusion Diagnostics is a medical technology company based in Lyon (France), that develops, manufactures and markets innovative patient monitoring systems. The core focus of APD is to provide relevant indicators pertaining to tissue perfusion to clinicians. The recent market introduction of IKORUS® monitoring system addresses a unmet need up to now, and opens new fields of investigation for physicians, enabling early detection of microcirculatory alterations and potential improvement of current therapeutic practices.

Minoryx Therapeutics is a biotechnology company based in Mataro, Spain, founded in 2011. The company specializes in discovering and developing innovative treatments for life-threatening rare diseases, with a particular focus on pediatric neurometabolic conditions of genetic origin. Minoryx is known for its development of pharmacological chaperones, a new generation of small molecule drugs designed to restore protein functionality, thereby addressing unmet medical needs in genetic diseases that severely affect the central nervous system. Additionally, Minoryx engages in repositioning-based projects to explore alternative therapeutic options for these challenging conditions.

Asceneuron SA is a biotechnology company based in Lausanne, Switzerland, founded in 2012. It specializes in the discovery and development of therapeutics for neurodegenerative disorders, particularly focusing on conditions with significant unmet medical needs, such as progressive supranuclear palsy, orphan tauopathies, Alzheimer's disease, and Parkinson's disease. Asceneuron aims to address the challenges posed by tauopathies, which are currently untreatable and characterized by the accumulation of tau protein deposits in the brain, leading to severe neurodegeneration. The company seeks to develop small molecule drugs that can provide effective treatment options, as existing therapies for Alzheimer's disease and related conditions offer limited benefits. With an increasing aging population, the burden of neurodegenerative diseases is expected to grow, highlighting the urgent demand for innovative and better-tolerated therapeutic solutions. Asceneuron operates as a subsidiary of Merck KGaA, reinforcing its commitment to advancing treatments in this critical area of healthcare.

PathoQuest SAS, a biotechnology company, offers a game changing metagenomics approach to improving the breadth of pathogen detection. The company offers products, such as (NGS) based testing approach delivers actionable reports to clinicians, biologists, and biopharmaceutical quality assurance managers and production managers. It provides iDTECTTM Dx Blood test, an approach to the identification of pathogens and iDTECTTM database and software suite that enables clinicians and biopharma companies to overcome the current limitation of infectious agent detection. The company also offers Viral Safety testing service for biopharmaceutical companies. It has strategic alliance with Charles River Laboratories International, Inc. PathoQuest SAS was founded in 2010 and is based in Paris, France.

Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse). Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.

BliNK Biomedical SAS specializes in the discovery and development of first or best-in-class antibody-based therapeutics for life threatening diseases such as cancer with a focus on immuno-oncology disease targets. Our lead program is a monoclonal antibody that targets an immune checkpoint to cause an immune switch that renders tumors susceptible to the body's immune system. Our other programs address a number of attractive, novel immuno-oncology and immune-checkpoint targets, some of which are unique to our approach. The antibodies that we are developing have the potential to be the next generation of anti-tumor therapeutics.

Xeltis AG operates as a clinical-stage medical device company that develops bio-absorbable heart valves and blood vessels. The company’s RestoreX, a polymer-based technology enables the patient's natural healing system to develop tissue that pervades Xeltis' heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis AG was founded in 2006 and is headquartered in Zurich, Switzerland with an additional R&D and manufacturing location in Eindhoven, the Netherlands.

AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.

Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player in the funding of healthcare and biotechnology in Europe.

OxThera AB manufactures products for the treatment of primary and secondary hyperoxaluria with bacteria and enzymes. It offers Oxabact, an orally delivered composition of live bacteria to promote the removal of endogenously produced oxalate for the treatment of primary hyperoxaluria and Oxazyme, a non-systemic orally delivered drug composed of recombinant oxalate decarboxylase for the treatment of dietary hyperoxaluria and prevention of kidney stones. The company was founded in 2005 and is based in Stockholm, Sweden with an additional location in Knoxville, Tennessee.

PathoQuest SAS, a biotechnology company, offers a game changing metagenomics approach to improving the breadth of pathogen detection. The company offers products, such as (NGS) based testing approach delivers actionable reports to clinicians, biologists, and biopharmaceutical quality assurance managers and production managers. It provides iDTECTTM Dx Blood test, an approach to the identification of pathogens and iDTECTTM database and software suite that enables clinicians and biopharma companies to overcome the current limitation of infectious agent detection. The company also offers Viral Safety testing service for biopharmaceutical companies. It has strategic alliance with Charles River Laboratories International, Inc. PathoQuest SAS was founded in 2010 and is based in Paris, France.

Safe Orthopaedics SA, a medical technology company, develops and markets sterile implants and single-use instruments for the treatment of spinal fracture pathologies in France and internationally. The company offers SteriSpine PS, an all-round kit for the treatment of spinal fractures and degenerative pathologies; and SteriSpine VA, a product platform for ready to use Kyphoplasty and Cement systems. It also provides SteriSpine LC, a ready to use instrumentation for lumbar cage portfolio, including Cedar and Elm; and SteriSpine CC, a ready to use instrumentation for cervical cage, such as Walnut. The company was founded in 2010 and is headquartered in Éragny-sur-Oise, France.

STAT-Dx Life S.L. is a Barcelona-based company that specializes in the development, manufacturing, and marketing of molecular diagnostic systems. Established in 2010, the company focuses on creating near-patient testing products aimed at providing timely and efficient patient care, particularly in critical care environments. Its flagship product, the DiagCORE, is a portable multi-analyte instrument designed for molecular and immunoassay testing across various clinical settings. STAT-Dx offers several diagnostic panels, including the DiagCORE Cartridge for syndrome testing, the DiagCORE Analyzer for modular analysis, and specific panels for respiratory, gastrointestinal, central nervous system, pneumonia, and blood culture identification. In 2018, STAT-Dx became a subsidiary of QIAGEN N.V., further enhancing its capabilities in the diagnostics field.

AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.

ABM Pharma is a partner of the entire pharmacy network in the home care of patients, today more than 5000 pharmacies are clients. ABM Pharma technicians work with more than 30,000 patients.

Asarina Pharma AB (publ) researches and develops pharmaceutical products. Its flagship product is Sepranolone that is in Phase IIb clinical trial to treat premenstrual dysphoric disorder and menstrual migraine. The company was formerly known as Umecrine Mood AB and changed its name to Asarina Pharma AB (publ) in 2016. Asarina Pharma AB (publ) was incorporated in 2005 and is based in Solna, Sweden.

PathoQuest SAS, a biotechnology company, offers a game changing metagenomics approach to improving the breadth of pathogen detection. The company offers products, such as (NGS) based testing approach delivers actionable reports to clinicians, biologists, and biopharmaceutical quality assurance managers and production managers. It provides iDTECTTM Dx Blood test, an approach to the identification of pathogens and iDTECTTM database and software suite that enables clinicians and biopharma companies to overcome the current limitation of infectious agent detection. The company also offers Viral Safety testing service for biopharmaceutical companies. It has strategic alliance with Charles River Laboratories International, Inc. PathoQuest SAS was founded in 2010 and is based in Paris, France.

Meiogenix SAS operates as a biotech company that develops breeding and genomic technologies. It offers SpiX technology, which modulates the process of homologous recombination in the genome by increasing its frequency in cold regions and PhoeniX, which is a non-GM method that induces meiotic recombination in hybrid diploid (or polyploid) yeast cells without the need to go through the entire process of meiosis. The company helps to develop new products to address global food and industrial challenges. The company was incorporated in 2010 and is based in Paris, France.

Safe Orthopaedics SA, a medical technology company, develops and markets sterile implants and single-use instruments for the treatment of spinal fracture pathologies in France and internationally. The company offers SteriSpine PS, an all-round kit for the treatment of spinal fractures and degenerative pathologies; and SteriSpine VA, a product platform for ready to use Kyphoplasty and Cement systems. It also provides SteriSpine LC, a ready to use instrumentation for lumbar cage portfolio, including Cedar and Elm; and SteriSpine CC, a ready to use instrumentation for cervical cage, such as Walnut. The company was founded in 2010 and is headquartered in Éragny-sur-Oise, France.